Biopharmaceutical companies continue to enjoy a banner year, and the sector as a whole remains a favorite with investors, a fact confirmed by Jefferies analyst Michael Yee, who wrote that "the biotech sector [is] seeing an increase in money flow and better performance vs. the broader market and other health care sectors."